Edwards Lifesciences
Irvine, CA 92614
Edwards PASCAL Transcatheter Valve Repair System Receives European Approval for Tricuspid Repair
Irvine, Calif., May 18, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation (TR). Although the prevalence...
Read More »Edwards PASCAL Transcatheter Valve Repair System Receives European Approval for Tricuspid Repair
Irvine, Calif., May 18, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation (TR). Although the prevalence...
Read More »Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients
Superior TAVR Valve Available for All Patients Diagnosed with Severe, Symptomatic Aortic Stenosis IRVINE, Calif., Aug. 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3...
Read More »Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients
Superior TAVR Valve Available for All Patients Diagnosed with Severe, Symptomatic Aortic Stenosis IRVINE, Calif., Aug. 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3...
Read More »Edwards SAPIEN 3 Valve Proves Superior to Surgery in Partner 3 Trial
NEW ORLEANS, March 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the results of the randomized PARTNER 3 Trial demonstrated superiority for the SAPIEN 3 transcatheter aortic valve over outcomes with surgery. The trial, which compared treatment...
Read More »Edwards SAPIEN 3 Valve Proves Superior to Surgery in Partner 3 Trial
NEW ORLEANS, March 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the results of the randomized PARTNER 3 Trial demonstrated superiority for the SAPIEN 3 transcatheter aortic valve over outcomes with surgery. The trial, which compared treatment...
Read More »Edwards PASCAL Transcatheter System Receives CE Mark
Irvine, Calif., Feb. 19, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the Edwards PASCAL transcatheter valve repair system has received CE Mark for the treatment of patients with mitral regurgitation. Mitral valve disease is complex, varied and...
Read More »Edwards PASCAL Transcatheter System Receives CE Mark
Irvine, Calif., Feb. 19, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the Edwards PASCAL transcatheter valve repair system has received CE Mark for the treatment of patients with mitral regurgitation. Mitral valve disease is complex, varied and...
Read More »Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Irvine, Calif., Dec. 28, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the SAPIEN 3 Ultra system has received U.S. Food and Drug Administration (FDA) approval for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients...
Read More »Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Irvine, Calif., Dec. 28, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the SAPIEN 3 Ultra system has received U.S. Food and Drug Administration (FDA) approval for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients...
Read More »Edwards PASCAL Transcatheter Valve Repair System Receives European Approval for Tricuspid Repair
Irvine, Calif., May 18, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation (TR). Although the prevalence...
Read More »Edwards PASCAL Transcatheter Valve Repair System Receives European Approval for Tricuspid Repair
Irvine, Calif., May 18, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation (TR). Although the prevalence...
Read More »Edwards SAPIEN 3 TAVI Receives Expanded Approval in Europe
Superior TAVI Valve Indicated for All Patients Diagnosed with Aortic Stenosis Irvine, Calif., Nov. 6, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the...
Read More »Edwards SAPIEN 3 TAVI Receives Expanded Approval in Europe
Superior TAVI Valve Indicated for All Patients Diagnosed with Aortic Stenosis Irvine, Calif., Nov. 6, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the...
Read More »Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients
SAN FRANCISCO, Sept. 29, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced new data demonstrating early and sustained health status advantages for severe aortic stenosis (AS) patients at low surgical risk treated with the Edwards SAPIEN 3 valve. Study results...
Read More »Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients
SAN FRANCISCO, Sept. 29, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced new data demonstrating early and sustained health status advantages for severe aortic stenosis (AS) patients at low surgical risk treated with the Edwards SAPIEN 3 valve. Study results...
Read More »Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients
Superior TAVR Valve Available for All Patients Diagnosed with Severe, Symptomatic Aortic Stenosis IRVINE, Calif., Aug. 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3...
Read More »Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients
Superior TAVR Valve Available for All Patients Diagnosed with Severe, Symptomatic Aortic Stenosis IRVINE, Calif., Aug. 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3...
Read More »Edwards Comments on Updated TAVR National Coverage Determination
IRVINE, Calif., June 21, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today commented on the final updated U.S. Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) pertaining to transcatheter aortic valve replacement (TAVR) programs:...
Read More »Edwards Comments on Updated TAVR National Coverage Determination
IRVINE, Calif., June 21, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today commented on the final updated U.S. Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) pertaining to transcatheter aortic valve replacement (TAVR) programs:...
Read More »